Beijing Konruns Pharmaceutical
Beijing Konruns Pharmaceutical is a Chinese developer in Beijing that sponsors 5 registered cancer trials of KC1036 and S-1.
Overview
Beijing Konruns Pharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 5 interventional cancer trials (phase 1/2, 2, 3), testing KC1036, S-1, Toripalimab in esophageal squamous cell carcinoma, esophageal squamous cell carcinoma (escc), digestive system tumors, thymic tumors. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Similar pages
not linked directly; found by shared links- TreatmentKC1036
Shares A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma, A Study of KC1036 in Patients with Advanced Thymic Tumors, A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer, KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer.
- CompanyBeijing Gene Key Life Technology
Shares the tags china, registry-only.
- CompanyBeijing Mabworks Biotech
Shares the tags china, registry-only.
- CompanyBeijing Pearl Biotechnology Limited Liability Company
Shares the tags china, registry-only.
- CompanyBeijing Scitech-Mq Pharmaceuticals
Shares the tags china, registry-only.
- CompanyBeijing Tide Pharmaceutical
Shares the tags china, registry-only.
- CompanyBinhui Biopharmaceutical
Shares the tags china, registry-only.
- CompanyChengdu Zenitar Biomedical Technology
Shares the tags china, registry-only.